Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H25ClO2 |
| Molecular Weight | 344.875 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)[C@H]1CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)C=C[C@@]4(C)[C@@H]3CC[C@]12C
InChI
InChIKey=USXVMPAWZOOYDE-OAYGGAORSA-N
InChI=1S/C21H25ClO2/c1-12(23)15-4-5-16-14-11-19(22)18-10-13(24)6-8-21(18,3)17(14)7-9-20(15,16)2/h6,8,10-11,14-17H,4-5,7,9H2,1-3H3/t14-,15+,16-,17+,20+,21-/m0/s1
| Molecular Formula | C21H25ClO2 |
| Molecular Weight | 344.875 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Trengestone is a steroid substance, a retroprogesterone. It has a strong progestogenic action and stimulating effect on the hypotalamo-hypophyseal system. It does not possess a direct oestrogenic or androgenic action. It indirectly stimulates the oestrogen productivity in the ovary via the central nervous system. The mechanism of action for induction of ovulation is not clear. It is indicated for the treatment of normooestrogenic anovulation. Ovulation occurs after trengestone administration either immediately ater termination of treatment or much later. Another indication for its administration are other functional disorders of the cycle and treatment of imminent abortion. Side-effects are: mastalgia, headache and fatigue.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:15 GMT 2025
by
admin
on
Mon Mar 31 18:06:15 GMT 2025
|
| Record UNII |
VY6S496SVX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C776
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID101023713
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
2757
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
3623
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
m11016
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | Merck Index | ||
|
5192-84-7
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
C66621
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
56840930
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
225-978-8
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107518
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
VY6S496SVX
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
Trengestone
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
SUB11233MIG
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY | |||
|
100000077501
Created by
admin on Mon Mar 31 18:06:15 GMT 2025 , Edited by admin on Mon Mar 31 18:06:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |